Recently, many studies have found that inhibition of bromodomain-containing protein 4 (BRD4) with pharmacological BET-specific bromodomain (BD) inhibitors can effectively block MYC expression in multiple myeloma, acute myeloid leukemia, and Burkitt's lymphoma 27-29. The gene discussed is BRD4; the disease is acute myeloid leukemia.